0:00Hey, guys. Welcome to the MSL talk podcast. Very excited. Guys, we're gonna this is an amazing, amazing topic with an amazing guest. We're gonna talk today about interactive treatment algorithms. The future is here. This is an incredibly exciting conversation with doctor Simon Chowdhury. He's chief medical officer at Open Medicine. Simon, welcome. Thank you, Tom. Too kind. It's lovely to see you again, and I'm looking forward to to chatting and, talking about many
0:33aspects of medical education innovation, including open medicine. So thank you for having me on your show. Can't wait. I cannot wait. Why don't we do an introduction? Why don't you tell everybody, you know, who you are, where you're from, and what you do, and all that good stuff? Thank you. So I'm a I'm a medical oncologist, a GU medical oncologist. I'm based out of London where where I had my big clinical practice. That's very small now. I do a bit of medical research through the medical research council. I did some of my training in Boston, so I did a fellowship with Dana Farber, still have very strong contacts there.
1:04And I think sort of the last ten years, I've been really focused on the aspect of medical education of taking knowledge and getting it from academic centers actually out to patients who are mainly treating the community. That's really been a focus for me. So I think and that's I think we're gonna talk about that. So that's a passion for me, and this is a passion project. I can't wait. I can't wait to jump into this. I am so excited. I've been looking forward to this for a very long time. Before we get into it, I I wanna just mention that this episode is sponsored by Open
1:35Medicine. So Open Medicine is where leading doctors post living algorithms to share their knowledge. So instead of static diagrams and PDFs, living algorithms are mobile first, interactive, and updated in real time as new clinical evidence emerges. And we're gonna talk about this and what interactive treatment algorithms are. Really, really exciting stuff. So check them out at myopenmedicine.com.
2:10So it's m y openmedicine.com. So, alright, Simon, why don't like, why don't you talk a little bit you mentioned that you're a GU oncologist. Can you talk a little bit specifically about your expertise? Yes. I mean, so, basically, I started geomedic oncology, so focused on prostate cancer, bladder urothelial cancer, kidney cancer, and testicular cancers, gosh, probably almost thirty years ago now. So, I'd always been interested in oncology, and then I was very fortunate that my mentors sort
2:43of said to me there's a big there's an evolution coming in prostate cancer. Why don't you be at the front of it? And I was fortunate enough to spend some time in Dana Farber with Phil Cantoff and then Tony Schwery, two spectacular people, good friends, great mentors. And then coming back to London, working with particularly with a guy called Paul Ellis, who's a very big breast cancer doctor. And Paul was like, you know, breast cancer, prostate cancer, they're not that dissimilar, but prostate cancer got a long way to go. So I led a lot of the of the large clinical trials, but it was in 2019 actually chatting
3:16with super guy called Mark Mark Wildgust from from from J and J who's I think they're one of their global medical affairs leads now. And Mark sort of said to me, you're talking about the New England Journal of Medicine paper like it like it makes a difference. Like, it makes much more of a difference than it does. The implementation uptake is really slow. In academic centers, it happens, and it's moderately good. But in the community, it takes a long time. And a lot of and Mark wasn't like this. He's a very he's a very, collegiate person. He's very, very much how can we adapt to the community.
3:49But I think a lot of academic people, and I was one of them, were quite dismissive of the community and were like, oh, you know, pharma this, community that. Actually, you know, the community and the pharma people, they're really good. They're decent people, like everywhere. Lots of really good people. And I think as academics have kind of done, I call it like academic grandstanding and trying to show how clever we are and the academic echo of I'll chat to Tom, who'll chat to Sarah, who'll chat to Sean. And we all work in Boston, New York, London, Paris. And actually, most of the treatment is happening in Florida, in Yorkshire where my mom
4:22was, in Dusseldorf, in places outside of the big academic centers. So how can we get that that knowledge that's in, you know, say a thought leader in in in Boston? How can we take that knowledge and put it in a format that makes the really good community doctors, you know, out in I never know what's the place to say in The US without it sounding. But in the community where most of the treatment happens and patients love their doctors there and have a real affiliation, how how can we get it to the patients, the community so that they benefit as quickly as patients in academic centers sometimes do?
4:56Yep. And I know Mark, actually. Oh. Or at least I know of him. I I have friends that have have been working on his team for many years. And, yeah, he's a big name and interesting how small it's just such a small community when you really break it down. Big industry, small community. So, Curly, talk talk to us about how leading physicians are staying up to date and and and actually interpreting the new oncology data as it emerges.
5:29Yeah. That's a really good question. I think I mean, the honest answer is I don't always know. And I think what I've seen is actually a lot of a lot of oncologists, a lot of the the academic oncologists and and the community, switched to x around the time of COVID. So I get most of my education from x. So I can tell you what I do and what I think people do. So I think for me, x is a brilliant form brilliant platform to learn from. But with the caveats that I think a lot of women, a lot of my female friends, feel feel
6:01very uncomfortable on there and often get really inappropriate messages. And also, it's not a safe environment. So people you know, I've got a thick skin. I'm also male. I'm I'm British. I have a British arrogance, confidence, whatever. So I don't mind if someone comes back to me and says, and y, you're rubbish. Most of the time, I'll just walk away. Sometimes I'll try and explain. But it's it's easy for me. Think for the younger doctors, for people who have less of a voice and less of a yeah. I'm a moderately big big voice in in the GU world, so I feel pretty confident interacting
6:33with, you know, the likes of Tony and Dana Farber, you know, people elsewhere. I think a lot of people don't have that luxury. So I think a lot of people I think there's a burnout in terms of there's so much we were talking about this before. There's so much information about publications has gone up exponentially. The quality hasn't, but the quantity has. So how do we distill that down into something that is that people are able to digest, understand, and then implement. I think the publication that I used to think was really was was was the final step in a
7:07pathway. There's probably chapter one or two, a big book. So what we need to do is take that New England publication, critique it, understand how good it is, understand the nuance of it, understand which patients it's gonna benefit, and then have something that sort of says, when you start drug x, start at this dose. These are the side effects you need to to deal with. These are the these are the labs you need to do beforehand. This is when you see your patient. If you get x side effect, then implement this. So and and although we're focusing on oncology to start with, we can do the whole of medicine.
7:39We've already started the metabolic medicine. Obviously, it's a massive thing around the GLP one drugs, both The US, The UK, and globally. And I think the GLP one drugs, a lot of my a lot of my cancer patients are using them because side effects of treatment for prostate cancer and breast cancer is weight gain and deconditioning. So I think it's how do we so I'm having to think about how I prescribe Menjaro Ozempic. I need a guide that takes me through it, and it says, this is the dose. When you get this, do this. This is the diet you should recommend. And and I think ultimately, we will aim to have something for patients as well because I think
8:12we're entering an era generation where people are where patient the patient voice should and will get louder. And I think you see this with with the GLP one drugs where a lot of people are using online pharmacies. You know, I think I think they said something I think in The UK, there's two million people on these drugs. Think I in The US, they said that forty million people have tried them. There's crazy amount of people, and there aren't that amount of doctors with expertise. Anyway, something I'm passionate about, so I'll I'll let you get a word in, Tom.
8:42Yeah. No. That that was great. A lot to unpack. And it's interesting to see that X has emerged as one of the primary data sources because there's there's so much out there now. And and and even as like, on the patient side, there's so much noise. And and there's so much there's direct to consumer, and there's there's so much information out there through, know, social media outlets, online sources Yep.
9:13And everything else. But when it comes to getting back to the to this discussion of of data and and how information is actually communicated and the most important information, We look at traditional sources, like congress presentations and and journal publications and guidelines. Yep. Where do they fall short in helping physicians make real world treatment decisions?
9:43Because I think that's where a lot of physicians Yep. Are still going. I think they're great, but I think they are targeted at academics like myself. I don't really like thinking of myself as an academic. I like think more about as a knockabout person, but I worked in a teaching hospital. Apologies. I worked in a teaching hospital, and I, you know, I'm in London, a center where there's lots of expertise. You know, I go to Boston a lot. I think where they fall short I think they're very good, but I think they are what I would call the academic echo.
10:13So they they play to people in academic centers. And I think they don't ask the the the guys and girls in the community because they don't come to the congresses. They're expensive. The publications are often paywalled and with institutions. You know, it's $50 to look at look at a publication. And then do you have time to read 12 pages? I mean, you know, we're all busy. People I think what we've seen is the explosion in terms of number of patients and also the complexity. I I did a lot of lung cancer back in in my training.
10:46It was it was a platinum doublet and then docetaxel. There was no targeted therapies. There was no immunotherapy. There was no ALK, ROS, EGFR, etcetera. So the world has become much more complicated, and the treatments of lung cancer, great example, prostate cancer, breast cancer, myeloma, they've changed. The last twenty, thirty years has been brilliant for patients, but it's complex and hard for doctors. And I think, yeah, how do I think what we fall short from is there's a there's a there's an assumption of knowledge.
11:17And I think people people don't like you you know, I love going to I love saying to the great and the good. I don't understand it. Make it a bit simpler for me. And that's hard. I think it was Einstein who said, if you understand something really well, you can explain it simply. A lot of people can't. So what we're aiming to do is to really strip it back, take out the complexity to a degree, and just make it really user friendly. So that if you said to me, you know, I've got a friend with I've got a friend with with myeloma, and they're gonna go on to a CAR T therapy. Can I learn something about it?
11:48I would hopefully say to you, yeah, go to our website, have a look through it. You'll get Vincent Raj Kumar, pretty much the leading person in the world. Vincent's a super ex educator. Smart, humble, great at communication. And then strip it back and kind of I hope we'll have something that that becomes interactive for both patients and doctors. But I think going back to what you were saying about x, I think the difficulty with x, and you said about very intelligently said about the patient and so much stuff out there is how do you know what to trust? How do you know what's a trusted source?
12:19We want to be a trusted source. We don't want to be something that's that's that's vanilla or just, you know, just run of the mill. We'll have something that's got a bit of debate on there that's got different voices. But But it needs to be polite. It needs to be collegiate, and it needs to be something that is respectful to doctors and patients and other health care workers. Yeah. I love what you said about the assumption of knowledge. I think we we all just assume that the leading physicians just know everything.
12:49It's it's when we're moving at such a quick pace that it's it's hard to keep up. So that's why this is such a fascinating conversation, and there's so much nuance. It it's it's not always cut and dried. So and I know from from prior conversations that there's there's often a lag between the data release and the clinical application. So how does that gap impact patient care and physician confidence in decision making?
13:23Yeah. That's a really good question. I think there's a huge gap, and I saw it too. I think we're gonna talk about something very personal to me, my mother's care. But I think we I think, essentially, you have what's an innovation adoption curve. And I think doctors are very conservative for good and bad reasons. The the idiom so I think it's a global thing. The UK, we try and claim everything, as you know. But, you know, do no harm actually leads to don't change. And my cousin, who's a great primary care doctor said, you know you know what, doctors?
13:54We we know what we like, and we like what we know. So to change from drug or therapy, whatever it is, a to drug b, it takes a lot for us. And some of that is is good. We shouldn't just be switching and and, you know, just willy nilly. We should look at the data. We should understand the data. But I think even then, I remember when I was first I was a much younger doctor and didn't have quite the network I had, I came back from Boston, I was super lucky. I could I could pick up the phone to to Phil or Tony or Dana Farber and say, I'm about to start
14:27this therapy. What's the new ones? What day should I start? What should I look out for? I want to have something like that so that people who don't have my connections, my privilege. You know, people in the community often are often are sort of disempowered and disenfranchised, not through any fault of their own because the system plays to people like myself. You know, that's great for me. And I remember someone saying, Joy, during COVID, I was saying, well, I don't mind not traveling so much. And they said, we've already got your network, Simon. It's fine for you. For the younger people, the trainees, they need to do what you were doing twenty years ago.
14:59For the community folks, I don't think meetings like ASCO, ESMO are really geared as much to them as they should be. And I think, you know, we need to change, and I hope we'll be part of that change. That isn't to criticize established sources. I'm part of the establishment. But I think I've been fortunate enough to to work with different people outside of medicine. And I think you can learn, like like someone like yourself. I mean, you're part of you're you're you're part of the as you said, you're part of the community, but you're also you're also part of the solution.
15:32You know? Things like you're doing with a podcast are way of cascading knowledge, making it in a way that people, when they get up and they have a shave, they can listen to this. Or they're driving to work or they're picking up their kids, they can listen to your podcast. I think that's great, Tom. That is how we change things, not by producing 300 page guidelines that are hard to look at on your phone. I don't know about you. My friends always say I'm glued to my phone, which is kind of true. Feel a little bit of separation anxiety from it now during this podcast. But it's kind of it's good and bad, but I think there's good bits in it that we can use.
16:03I agree. I totally agree. I'm right there with you. But you you mentioned your mom, and and you told me a a personal story about your mom, which I think really highlights one of the challenges that we're facing today in health care. Can you would you mind sharing that with us? I don't wanna get too personal. I have I have to say to your audience, I might shed a few tears here. Mothers and their sons are very, very, very close to my mom, and it's it's a real credit to Tom that I felt comfortable in our initial pre pre pod conversation to speak to him about it. It's a real credit to you, Tom. Thank you for being so so engaging and so so collegiate.
16:37So based on my mom, probably about, well, about three years ago, phoned me up, and we would speak two, three times a week. And we're very close, and she's a great mother, but my dad was a great dad. And she sort of said, I'm a bit breathless. And she and my mom used to do five mile hikes and stuff like that. She said, breathless goes there. I said, that's a bit odd, mom. I said, go and get go and get some blood tests done. And I thought, in my mind, I thought you're anemic. And then I'd seen a patient. They had AML. So I thought, you're anemic. You've got AML, haven't you? I don't know why I thought that. And on Monday, phoned her and said, have gone and got your blood tests? And she said, yes. Yes. I have.
17:07You were overacting, but I did what you said because I know you worry. Anyway, next phone call I get, she's in the emergency room in the local community hospital, and she's been interviewed twice by the local TV because there's problems with being admitted. So she's on she's becoming a a TV star. And she said, I'm gonna have a bone marrow test because my platelets are are 15 and my hemoglobin's they're they're different units in The UK, but very low. But, basically, she's very anemic, very thrombocytopenic, very much she had a bone marrow problem. And she had a bone marrow sample done, and she had a diagnosis of AML, bizarrely enough.
17:40And she was being treated with drugs that are, you know, there's a drug called Venetoclax, which has made a big difference in AML. It's gone with the chemotherapy, azacitidine, and it's complicated, but it's it's a complicated for a prostate cancer doctor because it's three times a week. It's pretty intensive. My mom was 75 at the time. And I saw that the doctors, very nice people, really engaged, you know. She was being treated in the community in the North Of England in Yorkshire where I grew up. Great part of the world. And I sort of said to her mom, you know, I don't think they know what they're doing.
18:11And she was like, hey. You need to let these people do what they wanna do. So and they didn't. And after three weeks, she was getting better. She was back walking, and they sort of said, oh, no. Your repeat bone marrow shows no response, so we're going to discharge you to the hospice. And I said, look, you know, my mom, she was breathless, and now she's back walking four miles. You know, she's she doesn't look like a woman who needs to go to the hospice quite yet. And then we said, he really cares too much. You know, he's very good son, but, you know, the doctor's alright. And we said my mom had a very a very interesting attitude towards death. She was very much, I don't wanna live too long, and I don't wanna don't want to suffer, and I
18:45don't want to be a burden on you and your sister. Incredible woman. So anyway, so a month later, she was still alive. She was still back and doing very well, getting better. Her blood count normalized, and I could've said this. I emailed the I've emailed the doctors a few times. I think they thought it was a pain, and I I sort of said, look. Know? She's still alive. Her blood count's normalized. I think your your bone marrow is wrong. And they sort of said, no. No. It's quite common you get this flare phenomenon. Now I'm very fortunate. I can speak to the to the people in Boston, New York, London. I said, did get this flare phenomenon, these drugs? They went, no. No.
19:15Never seen it. And these people treated thousands of patients, much bigger centers. They've done the clinical trials, new Journal of Medicine paper. Anyway, to cut a very long story a little bit shorter, my mom had responded. She got put back on the drugs. She lived for another sort of eighteen months. And, you know, it it wasn't a happy ending. She's now she's now she's now passed. But and she loved the fact that I was right and the other doctors were wrong. But but it's just showed me that these were not bad people. They weren't lazy. They just they just didn't understand the the New England paper as well as they could have
19:47done. I read it in detail about the supplement, and I was like, she's responding. And, you know, medicine can be really simple. And I you know, as my professor of medicine said to me, he said, you know, Simon, 95% of the patient will tell you what's going on. And if you stop to listen, not always my strength, 99%. My mom went from being breathless to being fit again. She was clearly responding. And it just made me think that medicine is easier for some people. You know, I I I one of my friends said, you see the patterns.
20:19But this was like, if I'd said to you, Tom, yeah, how's mom now? How is she? Whatever. She'd have been you'd have been on. She's been doing very well, Simon. So it's kind of it's that it it just showed me and sorry to talk about it for so long. It just showed me that the problem wasn't with the doctors in the community. The problem wasn't with with academics like me doing the New England Journal of Medicine paper. It was building that bridge, taking the New England paper and putting it in a format that the doctors and the community could could work with. And that's what we're trying to do. So
20:49Yeah. Well, thank you for sharing that story. That that means a lot. And it's such a great it just really defines what we're talking about right now is that there it it's very, very easy for the even even the the top upper echelon and trusted physicians with every every good intention may get it wrong. And and and maybe it's because of the information.
21:21Maybe it's because of information overload. I mean, do you feel that physicians have trouble just managing the sheer volume of new data, especially in oncology? I think a 100% and not just oncology, to be honest, Tom. I think you you you hit the nail on the head. I think, unfortunately, we live in a we live we live in a brilliant time, but it's a bit like I was chatting to one of my godchildren, and I was saying, I grew up, it was three TV channels. So this particular sporting event was amazing.
21:53You know, we would watch every single game of Wimbledon, the US Open because it was alive on TV. And they were like, you watch every game. And it's just a different world now. And I think, to be honest, I think it's much harder for for younger people these days and for people of my generation because you have all this information, but it's kind of so much distraction. There's so much there's so much noise. How does one know what to listen to, what to read, what to go to? And I think clearly for your audience, they know that you're a trusted source and that's
22:25that's great. But I think we need to distill down things and make it much simpler. You know, as I said, I always love kind of saying to people, I'm very fortunate that I'm connected. I know. But I love saying, I don't understand what you're saying. Make it a simpler. That takes a lot of confidence and a lot of a lot of privilege to do that. Most people don't have that or the time or the effort. So I think we're drowning in knowledge. We need to we need to we need to make it easier for people. So let's talk about that. So if you could if you could because I know that this is a real area of expertise for you.
23:01So if you could talk about the ideal way or design an ideal way for physicians to learn and apply new data in real time, what would that look like? So I think first bit is to go to your audience. So our audience is trainees in the community. Go to them and ask them what works for them. I think one of the problems I've seen is people like myself designing what we think will work. That isn't how Apple would do it or, you know, whoever or, you know, any big brand. They would go to do a lot more market research.
23:33So that's that's something we've been doing. I think it's basically I think people use their mobiles much more now. So I think it'd be mobile friendly, something called that you're probably aware of, I wasn't told this, the UX experience, the user experience. Something that you can essentially, you know, click on with one hand. I've got my hand out here trying to do do that while you're doing something else. Because ultimately, we'll we live in a world of huge distraction, whether it's work, kids, family, whatever. A lot of us are having to parent up and down.
24:04We've got the complication of older generation, younger generation to look after. So it's hard for people. So I think something that that something that provides a definitive pathway that doesn't just give you everything and say, it's really comprehensive. Here's what you could do. It's saying, here's what this guy here's what this person does. So here's what here's what, say, Farah Raja, who's a leading breast oncologist in London. How does she treat breast cancer? What would she do with the HER two positive, ER positive 56 year old woman in front of her?
24:38And why would she do that? So, ultimately, it's having something that is much more user friendly. I think my fellow founder, Avik, hates PDFs, and that kinda he's brought that hatred to me. I never really thought PDFs were something to have a great opinion about one with her, but they're not great on mobile phones. They're not a great thing to click through. They work to a degree on computers. But, you know, who who has the time to have a computer open while they're seeing a patient? Or who has the time after a busy day to spend two, three hours going through and which paper
25:08do you look at? So I think the ultimate thing would be would be something that's condensed, has a great UX experience on a mobile phone, and is interactive, but also keeps going back to the audience and saying, what did you like about this? What did you what did you not like about that? And part of my joy in doing the this current role is working with experts in software, website design, search engine optimization to agree artificial intelligence, and really not understanding that world. And super smart people, you know, who are able to cut through it and say, this is why we're
25:41doing this. This is why we're doing something else. I've learned so much. A lot of it not around medicine, but about communication. Yeah. Well and and it's fascinating. And I know just in doing my research on on open medicine and the stuff that you and Avik are doing, and, shout out to Avik, by the way, who's, who's been a great friend to to this podcast and, a a great partner. I I'm fascinated by what you explained to me as living algorithms and and how they work in
26:15practice. And I would love for you to share that with the audience and tell them what that's all about. Thank you, Tom. And I think you did a very good job of explaining it right at the start. But to go back over it, what we saw was the algorithms which are essentially have always been filled the whole time I've been in medicine for, like, thirty years have been initially a written diagram, then an overhead, then a PowerPoint slide, but they've always been a flat image. And the reason we focus on algorithms was we looked at San Antonio breast cancer meeting, and one of our faculty, Ilana Schwam, from Dana Farber, super, super faculty person.
26:48She posted an algorithm there, and she builds beautiful algorithms. And it got over a million views on x, and we thought, wow. And then we looked at other algorithms. We saw that we're getting loads and loads of views, often by people who didn't who didn't who weren't necessarily contributing any content themselves because they they they just wanted to understand and learn. So what we're hoping to do from from living algorithms is take things from the from from twenty, thirty years ago that haven't evolved and bring them up up to date in the modern age. So we're hoping to have an algorithm that is click through a ball.
27:20So you start off let's say, you started with advanced prostate cancer in the castrate sensitive session setting, and then you can maybe have a box that says, is it we divide that into high or low volume on on the on the disease burden and that affects the treatment path would be go down. That we might look at, excuse me, molecular markers such as BRCA that might take us down a different route. But all the time you can click through on one hand on your phone and then maybe different aside. So it might have a little video of one of our leading faculty like Neeraj Agarwal from the
27:51Huntsman Center talking about this is what I do. This is why I do it. So I think things like the NCCN guidelines are great, but they're so comprehensive and so exhaustive and difficult to use in a clinical setting. You know, they are they are the ultimate large build PDFs. And the same with all the guidelines that are out there from societies. So we want to work with them and update those that information into a condensed format that that is much more alive, much more living when you when you work with it, but also the
28:22changes. So we know that the ASCO, there are going to be at least five practice changing or should be practice changing studies. What we want is our algorithm to update in real time as the presentation is is is done and the New England Journal of Medicine paper drops. We want to be able to just algorithm is very easy to update. It's to click on it, draw a new box in, and then put that in and say, okay. This this is now a new part of the treatment algorithm. And then we can build upon that and put in images, video content, etcetera.
28:53Again, a lot of this would be what our what our audience wants, but that's how we see it. And and how so I I mean, I think the stuff you guys are doing at open medicine is incredible, and I I could see that it's very different from the guidelines of n c NCCN. But how how does open medicine change the way physicians learn from each other and translate data into action at the point of care? So I think we want something that people can action at the point of care, and we want to be a trusted resource.
29:23And what we saw is that from from x, there were certain doctors who have huge followings. Because they're great communicators, often they are people, you know, say, Vincent Raj Kumar at the Mayo Clinic, Trini Shwari at at Dana Farber, Steven Lou in in lung cancer at University of Georgetown. These are people with with big followings. And why they've got big followings? Because they're really good at communicating complex information in a short in a short format. So I think it's taking what's in their brains and getting it into a format that is not no
29:56longer sort of two d, but evolves along those lines. And something that that people will be able to use in clinic, they'll be able to update, they'll be able to use in front of their patients if they want to or pre seeing the patient, but something that's easy to use. It's really hard to to read the New England Journal of Medicine paper in front of a paid patient or look at it or whatever. Again, you'll have a pretty good relationship. So I'm just going to at something in the paper and then scroll through 30 pages. We want something that you can just you can look at before or join if you feel comfortable, and it will help help guide you.
30:27And I think one of the bits around this is having a trusted person. I think in the modern world, having a data source that is anonymous in terms of doesn't say, this is Tom. Explain how you do x. I like generative AI, but I'll give you an example. There's a meningitis outbreak amongst teenagers in certain parts of The UK, or there was about a couple months ago. And one of my best friends phoned me up by my godson, and he said he said, you know, what should we do? He said, well, should we have this vaccine for Tom?
30:57And I looked it up on ChatGee PT, and it was very helpful. Actually, I thought that the answer was actually completely correct. But I said, well, it's Thomas, my godson. So I phoned up my cousin Bill, who I said is primary care physician, and we went through it. And he said, yeah. You're right. This is slight nuance around it. So I like Chatuchi PT. I'll trust it for wine recommendation. I won't trust it when my patients or my godson's concerned. I will go to a source that is that has greater credibility. And I think that's what we're trying to build is something with a known faculty that takes
31:28the best of of the latest software AI website design, but integrates it with humans. I call it blended blended intelligence. And it takes artificial intelligence, but uses the best of humanity and, you know, the voices there. And I know I know the passion. I know the mission. I know that what you're trying to do at open medicine from our conversations is is to ultimately advance the field of oncology. Can you talk about that and how you how you plan to do that?
32:00I mean, ultimately, it's to change the whole of medicine. So, you know, for us, it's a very ambitious project that Avik and I have. But for both of us, it's a passion project that we've been thinking about for a very long time, at least the last ten years. And I feel super you say as you rightly say, he's a super guy, and I feel very lucky to have him as a friend and as a as a fellow founder, as are the fellow founders, Eric and Ryan, super people. None of them doctors, and we've got great doctors back. So how do I see it changing things? Sorry to answer your question. I think it's taking that publication, that presentation, the New England publication, the
32:33ASCO plenary session, and putting it into a format that makes sense for people who are time restricted, who aren't at the conference, who don't read or subscribe to New England, putting it in a format that's open, free, not siloed with content that is really that they can really engage with and that they will help us drive and generate. And then ultimately, that they'll be able to comment on and feedback and, you know, from that perspective, really. I think it's about it's about making something that is much more user friendly.
33:04And then talk about the impact on patients. I mean, I it seems pretty obvious, but A 100100%. No. No. But it's really important. So I think the impact on patients can be many fold. I think to start off with, if we have a new therapy x that makes a big difference in survival outcome for patients, If that therapy has only been given at, like, my old hospital, Guy's hospital, or Dana Farber, or Moyersland Kettering, or MD Anderson, that impacts a certain percentage of patients. It's pretty low. It's probably of the order of ten to fifteen, maybe twenty percent of patients.
33:38Now, every patient is going to be suitable for that, but it's going be well over fifty percent of patients who are. And I think what we see is even with simple therapies and in prostate cancer we've seen with with endocrine hormonal therapies, they take it. And these are not complicated drugs to give. They are tablet drugs that were approved. This isn't a question of funding or or finances. This is a question of knowledge and confidence. So what we want to do is is build that knowledge and confidence with doctors who don't who aren't doing the clinical trials, who haven't treated 30 patients in a study, who
34:09don't have the resource of of of huge amount of fellows, pharmacists, nurses, all that safety net to to to to see the patient with. We're thinking about people who work in much less resourced areas out in the community. How do we make it easy for them? Because they're doing the majority of the work. So if we can make it easier for them to uptake a new therapy, that will impact on patients. As I said with open medicine, we're hoping to to have a patient facing part of it by the end of the year.
34:39So patients will be able to go to it and, again, have a trusted resource. I think for most, you know, if we look at cancer, it's it's these older people. It's and and those people are less familiar with with with with things such as degenerative AI. They trust it less, which is both a good and a bad thing. We want to have this resource that that helps them helps empower them. So I think some of it is empowerment to doctors who are not typically engaged or not typically empowered. And it's about patients. It's about giving patients the knowledge to go to their doctors and say, well, what about
35:11this? We saw a video by Tony Schwery, or we saw an algorithm by him. Made a lot of sense to us, and and why aren't we on that therapy? And there may be really good reasons why they're not. But I think often they're not really good reasons, and some of it is just we don't do that yet. We don't do that here. So I think we need to be we need to make it easy for people, for patients and for doctors. Yeah. And you're on your way. I mean, it certainly sounds like this has really become a platform to really simplify things more than anything else.
35:44And as you know, this this podcast audience is typically MSLs and medical affairs professionals. So for those folks listening, what opportunities does a platform like Open Medicine create in terms of the them being able to understand physician decision making and and generating meaningful insights? Yeah. No. I mean, really good question. I think, you know, first of all, huge thanks to the pharma community out there.
36:15I think sometimes they are portrayed often by doctors as being the enemy. They're certainly not. They're the people working with us to empower these new therapies. We would not have made the progress in cancer if we hadn't without them. So I think we want to work with them to understand that and understand gaps in the in the way that that knowledge is cascaded and therapies are are implemented. In terms of the data, I think some of it will be I think it will be very useful to look at the algorithms, comment on them, and kind of work with them to put data there. You know, we want to be independent, but we don't want to be exclusive.
36:49People in pharma have huge knowledge and understand the drugs often better than anyone. So for me, I will often speak to people in in the pharma industry say, what about this? Can you educate me on CAR T therapies, for instance? I think the other bit is we will collect data around who is looking at what. So we'll have a lot of data from doctors. I think that data could be very valuable to say, okay, this algorithm from, you know, from Steven Lube on on on out out positive or negative lung cancer. But he was looking at it, and what are they saying, and how many people are clicking
37:22through? And do we think that's actually changing prescribing patterns, And what what do people make of that? So we want to build something that is really, you know, really meaningful for people out there. And we need farm to work with farmers. So, you know, it's I really don't see it as doctors one side, pharma the other side. We still work together. You know? That's how I see it. Think, you know, I've been very fortunate with the people I've worked with inside the pharmaceutical industry. They've taught me a huge amount over the years and continue to do so. So I think it's how do we work with them to get the data that's important and impactful for
37:55them. I I'll tell you, you're doing amazing work. And I just wanna Simon, again, thank you for for coming on and sharing your wisdom and and your innovation. This team this is such an innovative concept to me. So so, basically, we talked about a lot, but so folks could just go to my openmedicine.com to get more information. Absolutely. And, you know, we welcome feedback. You know, we want people we're we're in our first I wouldn't say we're in an early stage of
38:25development because Eric, our chief product officer, has worked incredibly hard. And it's not always easy with those doctors as the MSL audience will know. People are time poor. They don't always do what they say they're gonna do. Apologies to the MSLs I work with if I've I've let you down. Don't be ever afraid to ask. You guys are great. So I think I think go to the website. We want your feedback. We want your interactions. We wanna understand what people think about it. You know? So and we wanna work with you, and we want to build algorithms that are meaningful. There is no point I say one of the things I say, one of the jokes that we were doing beforehand is I realized when I was chatting to Mark Wildcust that it's like we're making music
38:58that no one listens to or that very few people listen to. And that's okay if you're an avant garde British punk band, but I wanna be Taylor Swift. I wanna get out there, get the message across, you know, really make a really make a change so that people like my mom don't suffer like they did unnecessarily. I think if you don't understand the nuance of the drugs, if you don't understand the therapy there's a new therapy out there, patients aren't gonna benefit from it. You don't understand the nuance and the toxicity management, you're going to have unnecessary toxicities, which my mom had as well. So it's kind of I see her when I'm doing this as well as lots of my patients.
39:30I get a lot of second opinions. And I used to be quite judgmental about it. And now I'm like, actually, it doesn't help anyone if I'm saying the doctor from x has done a bad job, and they haven't. And if they if they're not understanding it, people like myself need to really ask, look, ask ourselves some hard questions. Why are they not understanding what we're doing? We need to make it in a different format that's more accessible, more user friendly, and that's what we're trying to do. Well, I'm a fan. I'm gonna be listening to your music, and I might change the title of this. It's Simon Chaudhry, the the Taylor Swift of oncology.
40:04May maybe maybe that's the title. That's what I've always wanted. You know? So I I was I was in Nashville recently with Sarah Cannon people. I was like, when are we meeting Taylor? And they were like, maybe next visit. So Oh, man. You're amazing. Simon, thank you, and I'm actually looking forward to seeing you at ASCO. And and and wanna encourage you guys to check out MyOpenMedicine dot com. And and as always, if you got value in this, share it with others. I really appreciate all the support of this podcast. Thank you all.
40:34Love you all for listening, and we'll see you next time. Simon, thanks again. Thank you, Tom. Superb. Really enjoyed it.